The DMP Subcommittee has begun updating the requirements for the DMP COPD and, among other things, has asked manufacturers’ associations to propose “suitable digital medical applications” as appropriate.
The rules of procedure do not provide for an open application window for individual manufacturers. For manufacturers of a COPD-related digital application, this presents an opportunity for increased visibility and relevance in prescribing decisions within the physician’s treatment plan.
According to the rules of procedure, this does not apply only to DiGA under Section 33a of SGB V. Applications may be included in the suitability assessment if the following criteria are met:
- Target group clearly defined and relevant to the DMP indication
- Intended use: To support disease management by the patient
- The primary user is the patient
- Available at least in German
- Requirements under Section 2 of the DiGAV (security, functionality, data protection, data security, quality, interoperability) are demonstrably met. (This also applies to applications that are not DiGAs!)
Inclusion then occurs via a G-BA resolution in the respective DMP guideline. It is not time-limited; however, as part of the regular review of the DMP guidelines, the included applications are also re-evaluated.
Read the relevant GBA Rules of Procedure here: https://www.g-ba.de/downloads/62-492-4105/VerfO_2025-11-20_iK_2026-04-08.pdf